Company intelligence / Profile preview

Tarian Pharma

Grasse, Provence-Alpes-Côte d’Azur, Francetarianpharma.com ↗

Ownership: Private
Development stage: Other

Overview

Tarian Pharma is developing innovative topical small molecule drugs for the prevention and treatment of severe skin toxicities in cancer patients. Their lead candidate, TAR-0520, a novel topical formulation of brimonidine tartrate targeting the α2 adrenergic receptor, is advancing through Phase 1 and Phase 2 clinical trials for multiple oncodermatology supportive care indications. Preclinical and early clinical data support its safety profile and efficacy in reducing cutaneous adverse effects from cancer therapies.

Therapeutic areas: DermatologyOncology
Modalities: Small moleculeTopical drug formulationVasoconstrictor therapy (Brimonidine-based)
Industry: Biotech

Drug pipeline

1 asset

Tarian Gel

Unknown

Partnerships

Bpifrancei-LAB Competition/BPI FrancePaca‑Est Incubator

Beyond the preview

Go deeper on Tarian Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tarian Pharma.

Explore the full profile